Evidence map›Paper›PMID 41745284›Full record

ReviewJournal of fungi (Basel, Switzerland)2026

Stress-Activated Protein Kinase Pathways as Potential Targets for the Development of New Antifungals.

Rebeca Alonso-Monge, José Pedro Guirao-Abad, Juan Carlos Argüelles

Abstract readReview
In one paragraph

Review in Journal of fungi (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Rebeca Alonso-MongeUnidad de Microbiología, Departamento de Microbiología y Parasitología, Facultad de Farmacia, Universidad Complutense de Madrid, Plaza de Ramón y Cajal s/n, E-28040 Madrid, Spain.ORCID 0000-0001-8390-917X
José Pedro Guirao-AbadDivision of Basic and Translational Science, Department of Emergency Medicine, The Ohio State University Wexner Medical Center, Colombus, OH 43210, USA.ORCID 0000-0002-8417-9014
Juan Carlos ArgüellesÁrea de Microbiología, Facultad de Biología, Universidad de Murcia, E-30071 Murcia, Spain.ORCID 0000-0003-3376-3373

Funding

Ministerio de Economía y Com-petitividad (MINECO), Spain PID2021-122648NB-I00
6 · The paper itself

Abstract

The World Health Organization WHO considers fungal infections as a significant global risk that necessitates the development of new therapies. The arsenal of antifungals is limited, and the eukaryotic organization of fungi makes it difficult to find selective antifungal targets. In the search for potential targets for the design of new antifungals, the Stress-Activated Protein Kinase (SAPKs) pathways, and specifically, the two-component system, could be a plausible option since this upstream signaling system is absent in metazoans. SAPK pathways are involved in the response and adaptation to different environmental conditions. In pathogenic fungi, these signaling pathways are crucial for virulence, and some of them become activated in response to certain antifungals. Although further experimental evidence is required on the role of SAPKs in antifungal signaling and resistance, the possibility of impairing SAPK signaling by tagging the two-component system can be considered a useful strategy for implementing future antifungal therapies. In particular, the beneficial value of SAPK modulators combined with antifungal drugs should be a preferred line of research. In this review, we focused on the connection between the SAPK pathways and antifungal signaling in the four fungal priority pathogens,

Indexed as

antifungalshigh-priority fungal pathogensHOG pathwaystress-activated kinases (SAPK)

Identifiers

PMID41745284
PMCPMC12941646

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.